Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of Oral HTL0014242 in Healthy Adults
NCT03785054Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Nov 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TMP-301 in Fragile X syndrome (FXS), substance use disorder (SUD), amyotrophic lateral sclerosis (ALS) and 1 more (10 arms), sponsored by Nxera Pharma. Primary endpoint: Number of treatment related adverse events. Started Nov 2018; status: completed.
02
Drugs
TMP-301
03
Conditions
Fragile X syndrome (FXS)substance use disorder (SUD)amyotrophic lateral sclerosis (ALS)anxiety disorder
Beyond the preview
Go deeper on NCT03785054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785054.